Vasomotor Rhinitis in Children Under 18: When Initial Intranasal Treatment Has Not Achieved Symptom Control
Clinical Scenario
This protocol addresses vasomotor rhinitis in paediatric patients — children younger than 18 years — where initial intranasal pharmacotherapy has not produced adequate relief. In this age group, preventive and non-pharmacologic measures are the preferred first step before any medication is introduced.
Previous Treatment — Insufficient Response
The prior regimen may have included topical anticholinergic ipratropium (Atrovent) intranasally, nasal corticosteroid mometasone furoate (Nasonex) intranasally, or cromolyn sodium (Intal) intranasally. When these agents have not delivered meaningful reduction in rhinorrhea, adequate relief of congestion and nasal obstruction, or a decrease in sneezing, the next protocol step is warranted.
Next Step — Partial Overview
After prior intranasal agents have not achieved symptom goals, a judicious, time-limited trial of a carefully selected oral or topical agent class may be considered — approached with particular care in the paediatric setting. The full protocol specifies which options apply, the conditions for their use, and the relevant monitoring considerations.
References
- Preventive and nonpharmacologic approaches should be tried before beginning medication in children.
- If a therapeutic trial of one of these agents is attempted because of treatment failures with recommended agents, judicious and time-limited use should be considered.
View source ↗